Hepatitis Monthly

Published by: Kowsar

Elimination of Viral Hepatitis and an Update on Blood Safety Technology

Marijn Thijssen 1 , Marc Van Ranst 1 and Mahmoud Reza Pourkarim 1 , 2 , *
Authors Information
1 KU Leuven, Department of Microbiology and Immunology, Laboratory of Clinical and Epidemiological Virology, 3000, Leuven, Belgium
2 Blood Transfusion Research Centre, High Institute for Research and Education in Transfusion Medicine, Hemmat Exp. Way, 14665-1157, Tehran, Iran
Article information
  • Hepatitis Monthly: March 2018, 18 (3); e66577
  • Published Online: March 11, 2018
  • Article Type: Editorial
  • Received: January 22, 2018
  • Accepted: February 3, 2018
  • DOI: 10.5812/hepatmon.66577

To Cite: Thijssen M, Ranst M V, Pourkarim M R. Elimination of Viral Hepatitis and an Update on Blood Safety Technology, Hepat Mon. 2018 ; 18(3):e66577. doi: 10.5812/hepatmon.66577.

Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. History of Viral Hepatitis and Blood Safety
2. What Is Our Expectation?
3. New Methodology and New Challenges
4. Current Achievements
5. Conclusion
  • 1. Coppola N, Alessio L, Gualdieri L, Pisaturo M, Sagnelli C, Caprio N, et al. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. Euro Surveill. 2015;20(35):30009. doi: 10.2807/1560-7917.ES.2015.20.35.30009. [PubMed: 26530499].
  • 2. The Lancet Infectious D. Viral hepatitis: setting sights on the right target. Lancet Infect Dis. 2015;15(1):1. doi: 10.1016/S1473-3099(14)71064-3. [PubMed: 25541157].
  • 3. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med. 1967;66(5):924-31. doi: 10.7326/0003-4819-66-5-924. [PubMed: 4225883].
  • 4. Blumberg BS. Primary and secondary prevention of liver cancer caused by HBV. Front Biosci (Schol Ed). 2010;2:756-63. doi: 10.2741/s98. [PubMed: 20036981].
  • 5. Bukh J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol. 2016;65(1 Suppl):S2-S21. doi: 10.1016/j.jhep.2016.07.035. [PubMed: 27641985].
  • 6. Weusten J, van Drimmelen H, Vermeulen M, Lelie N. A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios. Transfusion. 2017;57(3pt2):841-9. doi: 10.1111/trf.14050. [PubMed: 28244600].
  • 7. Linauts S, Saldanha J, Strong DM. PRISM hepatitis B surface antigen detection of hepatits B virus minipool nucleic acid testing yield samples. Transfusion. 2008;48(7):1376-82. doi: 10.1111/j.1537-2995.2008.01698.x. [PubMed: 18422847].
  • 8. O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion. 2007;47(2):316-25. doi: 10.1111/j.1537-2995.2007.01108.x. [PubMed: 17302779].
  • 9. Hauser L, Roque-Afonso AM, Beyloune A, Simonet M, Deau Fischer B, Burin des Roziers N, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood. 2014;123(5):796-7. doi: 10.1182/blood-2013-09-524348. [PubMed: 24482503].
  • 10. Sobral PM, Barros AE, Gomes AM, do Bonfim CV. Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids. Rev Bras Hematol Hemoter. 2012;34(3):231-5. doi: 10.5581/1516-8484.20120056. [PubMed: 23049426].
  • 11. Sauvage V, Eloit M. Viral metagenomics and blood safety. Transfus Clin Biol. 2016;23(1):28-38. doi: 10.1016/j.tracli.2015.12.002. [PubMed: 26778104].
  • 12. Miri SM, Alavian SM. Epidemiology of hepatitis A virus infections in syria, 2017; war and asylum seekers: A global threat. Iran Red Crescent Med J. 2017;19(11). doi: 10.5812/ircmj.63622.
  • 13. Pourkarim MR, Vergote V, Amini-Bavil-Olyaee S, Sharifi Z, Sijmons S, Lemey P, et al. Molecular characterization of hepatitis B virus (HBV) strains circulating in the northern coast of the Persian Gulf and its comparison with worldwide distribution of HBV subgenotype D1. J Med Virol. 2014;86(5):745-57. doi: 10.1002/jmv.23864. [PubMed: 24532489].
  • 14. The L. Eliminating viral hepatitis: time to match visions with action. Lancet. 2017;390(10108):2121. doi: 10.1016/S0140-6736(17)32856-8. [PubMed: 29143741].
  • 15. Gonzalez R, Echevarria JM, Avellon A, Barea L, Castro E. Acute hepatitis B virus window-period blood donations detected by individual-donation nucleic acid testing: a report on the first two cases found and interdicted in Spain. Transfusion. 2006;46(7):1138-42. doi: 10.1111/j.1537-2995.2006.00863.x. [PubMed: 16836560].
  • 16. Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol. 2009;51(4):798-809. doi: 10.1016/j.jhep.2009.05.020. [PubMed: 19615780].
  • 17. Pourkarim MR, Sharifi Z, Soleimani A, Amini-Bavil-Olyaee S, Elsadek Fakhr A, Sijmons S, et al. Evolutionary analysis of HBV "S" antigen genetic diversity in Iranian blood donors: a nationwide study. J Med Virol. 2014;86(1):144-55. doi: 10.1002/jmv.23798. [PubMed: 24150816].
  • 18. Pourkarim MR, Van Ranst M. Guidelines for the detection of a common source of hepatitis B virus infections. Hepat Mon. 2011;11(10):783-5. doi: 10.5812/kowsar.1735143X.773. [PubMed: 22224075].
  • 19. Koppelman MH, Sjerps MC, Reesink HW, Cuypers HT. Evaluation of COBAS AmpliPrep nucleic acid extraction in conjunction with COBAS AmpliScreen HBV DNA, HCV RNA and HIV-1 RNA amplification and detection. Vox Sang. 2005;89(4):193-200. doi: 10.1111/j.1423-0410.2005.00691.x. [PubMed: 16262751].
  • 20. Amini-Bavil-Olyaee S, Pourkarim MR, Schaefer S, Mahboudi F, Van Ranst M, Adeli A, et al. Single-step real-time PCR to quantify hepatitis B virus and distinguish genotype D from non-D genotypes. J Viral Hepat. 2011;18(4):300-4. doi: 10.1111/j.1365-2893.2010.01308.x. [PubMed: 20367802].
  • 21. Zou S, Caler L, Colombini-Hatch S, Glynn S, Srinivas P. Research on the human virome: where are we and what is next. Microbiome. 2016;4(1):32. doi: 10.1186/s40168-016-0177-y. [PubMed: 27341799].
  • 22. Dwyre DM, Fernando LP, Holland PV. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang. 2011;100(1):92-8. doi: 10.1111/j.1423-0410.2010.01426.x. [PubMed: 21175659].
  • 23. Stramer SL. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser. 2014;9(1):30-6. doi: 10.1111/voxs.12070. [PubMed: 25210533].
  • 24. Kohl C, Brinkmann A, Dabrowski PW, Radonic A, Nitsche A, Kurth A. Protocol for metagenomic virus detection in clinical specimens. Emerg Infect Dis. 2015;21(1):48-57. doi: 10.3201/eid2101.140766. [PubMed: 25532973].
  • 25. Li L, Deng X, Mee ET, Collot-Teixeira S, Anderson R, Schepelmann S, et al. Comparing viral metagenomics methods using a highly multiplexed human viral pathogens reagent. J Virol Methods. 2015;213:139-46. doi: 10.1016/j.jviromet.2014.12.002. [PubMed: 25497414].
  • 26. Briese T, Kapoor A, Mishra N, Jain K, Kumar A, Jabado OJ, et al. Virome Capture Sequencing Enables Sensitive Viral Diagnosis and Comprehensive Virome Analysis. MBio. 2015;6(5):e01491-15. doi: 10.1128/mBio.01491-15. [PubMed: 26396248].
  • 27. Sauvage V, Laperche S, Cheval J, Muth E, Dubois M, Boizeau L, et al. Viral metagenomics applied to blood donors and recipients at high risk for blood-borne infections. Blood Transfus. 2016;14(5):400-7. doi: 10.2450/2016.0160-15. [PubMed: 27136432].
  • 28. Lau P, Cordey S, Brito F, Tirefort D, Petty TJ, Turin L, et al. Metagenomics analysis of red blood cell and fresh-frozen plasma units. Transfusion. 2017;57(7):1787-800. doi: 10.1111/trf.14148. [PubMed: 28497550].
  • 29. Furuta RA, Sakamoto H, Kuroishi A, Yasiui K, Matsukura H, Hirayama F. Metagenomic profiling of the viromes of plasma collected from blood donors with elevated serum alanine aminotransferase levels. Transfusion. 2015;55(8):1889-99. doi: 10.1111/trf.13057. [PubMed: 25721073].
  • 30. Kapoor A, Kumar A, Simmonds P, Bhuva N, Singh Chauhan L, Lee B, et al. Virome Analysis of Transfusion Recipients Reveals a Novel Human Virus That Shares Genomic Features with Hepaciviruses and Pegiviruses. MBio. 2015;6(5):e01466-15. doi: 10.1128/mBio.01466-15. [PubMed: 26396247].
  • 31. Berg MG, Lee D, Coller K, Frankel M, Aronsohn A, Cheng K, et al. Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection. PLoS Pathog. 2015;11(12). e1005325. doi: 10.1371/journal.ppat.1005325. [PubMed: 26658760].
  • 32. Sauvage V, Gomez J, Boizeau L, Laperche S. The potential of viral metagenomics in blood transfusion safety. Transfus Clin Biol. 2017;24(3):218-22. doi: 10.1016/j.tracli.2017.06.018. [PubMed: 28694025].
  • 33. Popgeorgiev N, Colson P, Thuret I, Chiarioni J, Gallian P, Raoult D, et al. Marseillevirus prevalence in multitransfused patients suggests blood transmission. J Clin Virol. 2013;58(4):722-5. doi: 10.1016/j.jcv.2013.10.001. [PubMed: 24183312].
  • 34. Uch R, Fournier PE, Robert C, Blanc-Tailleur C, Galicher V, Barre R, et al. Divergent Gemycircularvirus in HIV-Positive Blood, France. Emerg Infect Dis. 2015;21(11):2096-8. doi: 10.3201/eid2111.150486. [PubMed: 26488181].
  • 35. Ramamurthy M, Sankar S, Kannangai R, Nandagopal B, Sridharan G. Application of viromics: a new approach to the understanding of viral infections in humans. Virusdisease. 2017;28(4):349-59. doi: 10.1007/s13337-017-0415-3. [PubMed: 29291225].
  • 36. Guinoiseau T, Moreau A, Hohnadel G, Ngo-Giang-Huong N, Brulard C, Vourc'h P, et al. Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification. PLoS One. 2017;12(3). e0174852. doi: 10.1371/journal.pone.0174852. [PubMed: 28362878].
  • 37. McPhee F, Hernandez D, Zhou N. Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin. Antivir Ther. 2017;22(3):237-46. doi: 10.3851/IMP3120. [PubMed: 28008868].
  • 38. Ayres A, Yuen L, Jackson KM, Manoharan S, Glass A, Maley M, et al. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. J Viral Hepat. 2014;21(11):809-17. doi: 10.1111/jvh.12212. [PubMed: 24329944].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments